Literature DB >> 3732363

Cefodizime penetration into skin suction blister fluid following a single intravenous dose.

M Schäfer-Korting, H C Korting, L Maass, N Klesel, H G Grigoleit, E Mutschler.   

Abstract

Cefodizime pharmacokinetics was investigated, evaluating drug concentrations in serum, skin suction blister fluid (SBF), saliva and urine in six healthy male subjects who were administered a 1-g dose intravenously. Serum levels in five subjects can be described according to a two-compartment open model; terminal half-life is 181 +/- 14 min. Volume of distribution (Vd beta) amounts to 15.3 +/- 1.61, serum clearance to 59 +/- 6 ml/min, renal clearance to 33 +/- 3 ml/min. Of the administered dose, 54% is renally excreted unchanged within 27 h. Unbound drug fraction in serum is 19.0% and in SBF 38.4%. Thus renal clearance of free cefodizime amounts to 172 ml/min, Vdss to 68.9 l (free drug). Whereas cefodizime has not been detected in saliva samples, SBF concentration 3-9 h post administration parallel serum levels, amounting to 40% of the respective serum concentration. At 9 h, unbound cefodizime concentrations in SBF amount to 1.4 +/- 0.4 micrograms/ml, this value being well above the MIC90% values of many clinically relevant bacteria.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3732363     DOI: 10.1007/bf00541531

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Drug concentration in saliva.

Authors:  J C Mucklow; M R Bending; G C Kahn; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1978-11       Impact factor: 6.875

2.  Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults.

Authors:  A A Pollock; P E Tee; I H Patel; J Spicehandler; M S Simberkoff; J J Rahal
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

3.  Penetration of cefotaxime and desacetylcefotaxime into skin blister fluid.

Authors:  T Bergan; T Kalager; K B Hellum; C O Solberg
Journal:  J Antimicrob Chemother       Date:  1982-09       Impact factor: 5.790

4.  Intramuscular and intravenous pharmacokinetics of cefmenoxime, a new broad-spectrum cephalosporin, in healthy subjects.

Authors:  G R Granneman; L T Sennello; F J Steinberg; R C Sonders
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

5.  Plasma, cantharides blister fluid, and suction blister fluid levels of ceftizoxime after single intramuscular application for gonorrhea.

Authors:  H C Korting; M Schäfer-Korting; R Haag; E Mutschler
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1984-04

6.  Fraction unbound in interstitial fluid.

Authors:  P J McNamara; M Gibaldi; K Stoeckel
Journal:  J Pharm Sci       Date:  1983-07       Impact factor: 3.534

Review 7.  Third generation cephalosporins.

Authors:  B A Cunha; A M Ristuccia
Journal:  Med Clin North Am       Date:  1982-01       Impact factor: 5.456

8.  Suction blister fluid as a model for interstitial fluid in rats.

Authors:  M J Herfst; H van Rees
Journal:  Arch Dermatol Res       Date:  1978-12-01       Impact factor: 3.017

9.  Cefodizime, an aminothiazolylcephalosporin. II. Comparative studies on the pharmacokinetic behavior in laboratory animals.

Authors:  N Klesel; M Limbert; K Seeger; G Seibert; I Winkler; E Schrinner
Journal:  J Antibiot (Tokyo)       Date:  1984-08       Impact factor: 2.649

10.  Plasma and skin blister fluid levels of cefotiam and cefmenoxime after single intramuscular application of 1 g in gonorrhea.

Authors:  H C Korting
Journal:  Chemotherapy       Date:  1984       Impact factor: 2.544

View more
  7 in total

1.  Skin tissue fluid levels of cefotiam in healthy man following oral cefotiam hexetil.

Authors:  H C Korting; M Schäfer-Korting; F Kees; A Lukacs; H Grobecker
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Pharmacokinetic study of cefodizime and ceftriaxone in sera and bones of patients undergoing hip arthroplasty.

Authors:  F Scaglione; G De Martini; L Peretto; R Ghezzi; M Baratelli; M M Arcidiacono; F Fraschini
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

3.  An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review.

Authors:  C Jongmans; A E Muller; P Van Den Broek; B De Melo Cruz De Almeida; C Van Den Berg; J Van Oldenrijk; P K Bos; B C P Koch
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

Review 4.  Pharmacokinetic profile of cefodizime.

Authors:  D Brockmeier; E E Dagrosa
Journal:  Infection       Date:  1992       Impact factor: 3.553

Review 5.  Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; R N Brogden
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

6.  Multiple-dose pharmacokinetics of ofloxacin in serum, saliva, and skin blister fluid of healthy volunteers.

Authors:  R Warlich; H C Korting; M Schäfer-Korting; E Mutschler
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

7.  Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers.

Authors:  H C Korting; M Schäfer-Korting; L Maass; N Klesel; E Mutschler
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.